

2020 年

1. Naito A, Taguchi S, Suzuki M, Kawai T, Uchida K, Fujimura T, Fukuhara H, Kume H. Transient acute kidney injury observed immediately after robot-assisted radical prostatectomy but not after open radical prostatectomy. *Molecular and Clinical Oncology*, 2020, in press.
2. Inoue T, Okada S, Hamamoto S, Miura H, Matsuzaki J, Tambo M, Fukuhara H, Fujisawa M, Matsuda T, Nutahara K. Evaluation of flexible ureteroscope with an omni-directional bending tip, using a JOYSTICK unit (URF-Y0016); an ex-vivo study. *World Journal of Urology*, 2020, in press.
3. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, Suzuki M, Kume H, Fukuhara H. Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. *BMC Cancer*, 20, 371, 2020.
4. Okegawa T, Omura S, Samejima M, Ninomiya N, Taguchi S, Nakamura Y, Yamaguchi T, Tambo M, Fukuhara H. Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy: comparison of oncological outcomes at a single center. *Prostate Int.* 8, 16-21, 2020.
5. Tambo M, Taguchi S, Nakamura Y, Okegawa T, Fukuhara H. Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definition in obstructive pyelonephritis. *BMC Urol.* 20, 23, 2020.
6. Masuda K, Aizawa N, Watanabe D, Okegawa T, Kume H, Igawa Y, Fukuhara H. Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats. *Scientific Reports.* 10, 4182, 2020.
7. Kakutani S, Asamoto M, Araki F, Chen YN, Shinokawa M, Okagami Y, Ohata T, Taguchi S, Yamada Y, Takeshima Y, Kume H, Yamada Y, Aihara M, Ito N, Fukuhara H. Prospective evaluation of visual function in patients with ocular diseases after robotic-assisted laparoscopic prostatectomy. *Int J Urol.* 27, 307-313, 2020.
8. Tambo M, Inoue T, Miura H, Matsuzaki J, Nutahara K, Hamamoto S, Okada S, Fukuhara H, Fujisawa M, Matsuda T. A novel flexible ureteroscope with omnidirectional bending tip using joystick-type control unit (URF-Y0016): initial validation study in bench models. *J Endourol.* 2020, in press.
9. Shimizu T, Yamaguchi K, Yamamoto M, Kurioka R, Kino Y, Matsunaga W, Nakao S, Fukuhara H, Tanaka A, Gotoh A, Mabuchi M. Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug. *Bioorganic & Medicinal Chemistry Letter* 30, 126744, 2020.
10. Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibahara J, Fukuhara H, Komiyama M, Watanabe SI, Tamura K, Kawai A, Shibata T, Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. *Histopathology* 76, 509-520, 2020.

11. Taguchi S, Nakagawa T, Fukuhara H. Inconsistencies in currently used definitions of sarcopenia in oncology. *Annals of Oncology* 31, 318-319, 2020.

2019 年

12. Nakato R, Wada Y, Nakaki R, Nagae G, Katou Y, Tsutsumi S, Nakajima N, Fukuhara H, Iguchi A, Kohro T, Kanki Y, Saito Y, Kobayashi M, Izumi-Taguchi A, Osato N, Tatsuno K, Kamio A, Hayashi-Takanaka Y, Wada H, Ohta S, Aikawa M, Nakajima H, Nakamura M, McGee RC, Heppner KW, Kawakatsu T, Genno M, Yanase H, Kume H, Senbonmatsu T, Homma Y, Nishimura S, Mitsuyama T, Aburatani H, Kimura H, Shirahige K. Comprehensive epigenome characterization reveals diverse transcriptional regulation across human vascular endothelial cells. *Epigenetics Chromatin*. 12, 77, 2019.
13. Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Nakagawa K, Abe O, Kume H, Fukuhara H*. Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. *Radiother Oncol*. 140, 62-66, 2019.
14. Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K. In vivo rendezvous of small nucleic acid drugs with charge-matched block cationomers to target cancers. *Nat Commun*. 10, 1894, 2019.
15. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. *Neurourol Urodyn* 38, 1067-1075, 2019.
16. Akiyama Y, Daichi M, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. *J Urol*. 202, 290-300, 2019.
17. Kinjo M, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. *Urol Int*. 102, 331-335, 2019.
18. Taguchi S, Fukuhara H*, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. *Jpn J Clin Oncol*. 49, 201-209, 2019.
19. Samejima M, Taguchi S, Miyagawa S, Matsumoto R, Omura S, Ninomiya N, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Koba T, Matsuki R, Jimbo I, Motoyasu A, Tsumura T, Shimoyamada H, Shibahara J, Sakamoto Y, Fukuhara H. Acute hypotension induced by suction

of cystic fluid containing extremely high concentrations of catecholamines during resection of giant pheochromocytoma. *IJU Case Rep*, 2, 218-220, 2019.

20. Taguchi S, Nakagawa T, Fukuhara H. Re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. *Eur Urol* 2019. *Eur Urol*, S0302-2838, 30345-30348, 2019.
21. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. *Kidney Int*. 96: 159-169. 2019
22. Higashihara E, Yamamoto K, Kaname S, Okegawa T, Tanbo M, Yamaguchi T, Shigemori K, Miyazaki I, Yokoyama K, Nutahara K : Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases. *Clin Exp Nephrol*. 23, 100-111, 2019.
23. Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M : Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. *Sci Rep*. 9, 13218, 2019.
24. Fujisaki A, Kinjo M, Shimoinaba M, Honda S, Yoshimura Y. An evaluation of the impact of post-hysterectomy vesicovaginal fistula repair on the mental health of patients in a developed country. *Int Urogynecol J*. 2019, in press.
25. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. *Kidney Int*. 96, 159-169, 2019.
26. Gonda K, Akama T, Nakamura T, Hashimoto E, Kyoya N, Rokkaku Y, Maejima Y, Horita S, Tachibana K, Abe N, Ohtake T, Shimomura K, Kono K, Saji S, Takenoshita S, Higashihara E. Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report. *J Med Case Rep*. 13, 381, 2019.

2018 年

27. Fujimura T, Fukuhara H, Yamada Y, Taguchi S, Sugihara T, Niimi A, Nakamura M, Nakagawa T, Igawa Y, Homma Y, Kume H. Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. *Anticancer Res*. 38: 6529-6535, 2018.

28. Kinoshita Y, Sugihara T, Yasunaga H, Matsui H, Ishikawa A, Fujimura T, Fukuhara H, Ishibashi Y, Fushimi K, Homma Y. Hospital-volume effects on perioperative outcomes in peritoneal dialysis catheter implantation: analysis of 2,505 cases. *Perit Dial Int.* 38, 419-423, 2018.
29. Taguchi S, Fukuhara H*, Miyakawa J, Morikawa T, Naito A, Kawai T, Fujimura T, Kume H. Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. *Jpn J Clin Oncol.* 48, 692-694, 2018.
30. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. *Mol Clin Oncol.* 8, 665-670, 2018.
31. Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. *Jpn J Clin Oncol.* 48, 485-49, 2018.
32. Aizawa N, Watanabe D, Fukuhara H, Fujimura T, Kume H, Homma Y, Igawa Y. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relaxation with bladder myogenic contractions in male rats with bladder outlet obstruction. *Neurourol Urodyn.* 37, 1897-1903, 2018.
33. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y and Homma Y. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in patients with Hunner-type interstitial cystitis. *Neurourol Urodyn.* 37, 1441-1447, 2018.
34. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H and Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. *Neurourol Urodyn.* 37, 1113-1119, 2018.
35. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, Igawa Y, Homma Y. Predictors of Early Continence after Robot-assisted Radical Prostatectomy. *Low Urin Tract Symptoms.* 10, 287-291, 2018.
36. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. *World J Urol.* 36, 249-256, 2018.
37. Arakawa K, Hata K, Yamamoto Y, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Yoshida M, Fukuhara H, Fujishiro M, Morikawa T, Yamasoba T, Koike K, Fukayama M, Watanabe T. Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum,

- prostate, and external ear canal-without microsatellite instability: a case report. *BMC Cancer* 18, 24, 2018.
38. Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K. A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. *Clin Exp Nephrol.* 22(2):395-404, 2018.
 39. Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. *Prostate.* 78(8):576-582, 2018
 40. Fujita N, Tambo M, Terado Y, Fujita M, Okegawa T, Nutahara K. Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum. *Case Rep Oncol.* 4;11(1):6-10, 2018.
 41. Kinjo M, Yoshimura Y, Kitagawa Y, Okegawa T, Nutahara K. Sexual activity and quality of life in Japanese pelvic organ prolapse patients after transvaginal mesh surgery. *J Obstet Gynaecol Res.* 44(7):1302-1307, 2018
 42. Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. *Clin Exp Nephrol.* 22(5):1213-1223, 2018.
 43. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. *Low Urin Tract Symptoms.* 10, 148-151, 2018.